Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-I in Human Breast Cancer

TİMUR S. S., Bhattarai P., GÜRSOY R. N., VURAL İ., Khaw B.

PHARMACEUTICAL RESEARCH, vol.34, no.2, pp.352-364, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.1007/s11095-016-2066-2
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.352-364
  • Keywords: peptide-antibody bispecific complexes, polymer pro-drug conjugates, pre-targeted drug targeting, TARGETED DELIVERY, ANTIBODY, THERAPY, FUTURE
  • Hacettepe University Affiliated: Yes


Purpose LyP-1, a nine-amino-acid tumor homing peptide, selectively binds to its cognate receptor, p32. Overexpression of p32 in certain tumors should allow use of LyP-1 as a targeting agent for the delivery of therapeutic or diagnostic agents. Peptide conjugates are developed for enhanced pretargeting of MDA-MB-231 breast cancer cells with peptideantibody bispecific complexes and targeting with multipledrug/- fluorophore-conjugated nano-polymers.